In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.
Francesco Bertoni(Ente Ospedaliero Cantonale), F Cavalli(University of Insubria), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Anna Sasso(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Giancarlo Pruneri(University of Milan), Carlo C. Catapano(Institute of Oncology Research), Emanuele Zucca(Università della Svizzera italiana), Silvia Uccella(University of Insubria), Maria Grazia Tibiletti(University of Insubria), Maurilio Ponzoni(San Raffaele University of Rome)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k